Abstract
Estrogens have been recently postulated as potential agents in the development and progression of prostate cancer. Previous studies have demonstrated presence of both variants of estrogen receptor (ER); ER alpha (ERα) and ER beta (ERβ) in differing proportions between normal prostate and prostate cancer. It has been previously suggested that estrogens may either accelerate or inhibit growth of prostate cancer cell growth, depending on ER status. In particular, ERβ is considered to have a growth inhibitory role in prostate tissue. ERβ is significantly expressed in human prostate cancer cells, and hence it is considered a key factor for anti-cancer therapy. Therefore, various types of ERβ ligands have been investigated to clarify the mechanism of ERβ-mediated pathway of inhibitory effects on prostate cancer cells. Herein, we review recent examinations of ERs in prostate cancer, and the significance of ER mediated signaling pathways, with a focus on ERβ, as prospective therapeutic targets in prostate cancer.
Keywords: Estrogen receptor alpha(ERα), estrogen receptor beta (ERβ), GRP30, prostate cancer, steroid metabolism
Current Molecular Pharmacology
Title:Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy
Volume: 5
Author(s): Yasuhiro Nakamura, Keely M McNamara and Hironobu Sasano
Affiliation:
Keywords: Estrogen receptor alpha(ERα), estrogen receptor beta (ERβ), GRP30, prostate cancer, steroid metabolism
Abstract: Estrogens have been recently postulated as potential agents in the development and progression of prostate cancer. Previous studies have demonstrated presence of both variants of estrogen receptor (ER); ER alpha (ERα) and ER beta (ERβ) in differing proportions between normal prostate and prostate cancer. It has been previously suggested that estrogens may either accelerate or inhibit growth of prostate cancer cell growth, depending on ER status. In particular, ERβ is considered to have a growth inhibitory role in prostate tissue. ERβ is significantly expressed in human prostate cancer cells, and hence it is considered a key factor for anti-cancer therapy. Therefore, various types of ERβ ligands have been investigated to clarify the mechanism of ERβ-mediated pathway of inhibitory effects on prostate cancer cells. Herein, we review recent examinations of ERs in prostate cancer, and the significance of ER mediated signaling pathways, with a focus on ERβ, as prospective therapeutic targets in prostate cancer.
Export Options
About this article
Cite this article as:
Nakamura Yasuhiro, M McNamara Keely and Sasano Hironobu, Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy, Current Molecular Pharmacology 2012; 5 (3) . https://dx.doi.org/10.2174/1874467211205030008
DOI https://dx.doi.org/10.2174/1874467211205030008 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
BRCA Unclassified Variants: How Can They be Classified?
Current Women`s Health Reviews A Review of Animal and Human Studies for Management of Benign Prostatic Hyperplasia with Natural Products: Perspective of New Pharmacological Agents
Inflammation & Allergy - Drug Targets (Discontinued) Bioactive Polyphenols from Healthy Diets and Forest Biomass
Current Nutrition & Food Science Meet the Guest Editor
Combinatorial Chemistry & High Throughput Screening Implementing Cancer Exercise Rehabilitation: An Update on Recommendations for Clinical Practice
Current Cancer Therapy Reviews SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy Dynamic Contrast-Enhanced MRI in Oncology Drug Development
Current Clinical Pharmacology 1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy Prolactin and Blood-Brain Barrier Permeability
Current Neurovascular Research The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Adrenomedullin Expression in Alzheimer's Brain
Current Alzheimer Research Targeted Drug Delivery Systems for Lung Macrophages
Current Drug Targets Herbal Medicine of the 21st Century: A Focus on the Chemistry, Pharmacokinetics and Toxicity of Five Widely Advocated Phytotherapies
Current Topics in Medicinal Chemistry Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery Influence of Essential Trace Minerals and Micronutrient Insufficiencies on Harmful Metal Overload in a Mongolian Patient with Multiple Sclerosis
Current Aging Science Patent Selections:
Current Biomarkers (Discontinued) MT1-MMP Modulates bFGF-Induced VEGF-A Expression in Corneal Fibroblasts
Protein & Peptide Letters Molecular Imaging Probe Development Using Microfluidics
Current Organic Synthesis Mechano-Regulation of Alternative Splicing
Current Genomics